O0027 Rotigotine transdermal patch provides continuous efficacy in patients with moderate to severe idiopathic restless legs syndrome – 24 month results from a multi-national, multi-centre, open-label, follow-up trial

Trenkwalder, Claudia; Stiasny-Kolster, K.; Poewe, W.; Schollmayer, Erwin; Oertel, WH

doi:10.1016/s1389-9457(07)70213-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Comparative Efficacy1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with baseline, more than 95% of patients were “much” or “very much improved” on the CGI scale at 1 year. 24-26…”

Section: Comparative Efficacymentioning

confidence: 99%

Rotigotine Transdermal System

2007

View full text Add to dashboard Cite

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD-ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The October 2007 monograph topics are maraviroc, etravirine, bifeprunox, regadenoson, and fesoterodine. The DUE is on maraviroc.

show abstract

“…Compared with baseline, more than 95% of patients were “much” or “very much improved” on the CGI scale at 1 year. 24-26…”

Section: Comparative Efficacymentioning

confidence: 99%